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Abstract 
In earlier studies, cannabidiol (CBD), a major nonpsychotropic cannabinoid found 
in cannabis plant, has been shown to influence cardiovascular functions under various 
physiological and pathological conditions. In the present study, the effects of CBD on 
contractility and electrical properties of rat ventricular myocytes were investigated. Video 
edge detection was used to measure myocyte shortening. Intracellular Ca
2+
 was measured 
in cells loaded with the fluorescent indicator fura-2 AM. CBD (1 µM) caused a 
significant decrease in the amplitudes of electrically-evoked myocyte shortening and Ca
2+
 
transients. However, the amplitudes of caffeine-evoked Ca
2+
 transients and the rate of 
recovery of electrically-evoked Ca
2+
 transients following caffeine application were not 
altered. Whole-cell patch-clamp technique was employed to investigate the effect of CBD 
on the characteristics of action potentials (APs) and L-type Ca
2+
 channels. CBD (1 µM) 
significantly decreased the duration of APs. Further studies on L-type Ca
2+
 channels 
indicated that CBD inhibits these channels with IC50 of 0.1 µM in a voltage-independent 
manner. 
 
Keywords: Cannabidiol, I type calcium channels, ventricular myocyte. 
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Title and Abstract in Arabic 
الكهربية و االنقباضية الخاصة بالخاليا العضلية  على الخواص الكانابيديول آثار
 القلبية
 الملخص
في دراسات سابقة، الكانابيديول، و هو من المؤثرات العقلية الكانابينويدية الرئيسية الموجودة في نبات 
ف الظروف الفيسيولوجية و المرضية. الحشيش،  وجد أن له تأثيرات على وظائف القلب و األوعية الدموية تحت مختل
الهدف في هذه األطروحة هو دراسة اثار الكانابيديول على االنقباضات و الخصائص الكهربية لخاليا الفأر العضلية. 
Caو تم قياس انقباض الخاليا العضلية باالستعانة بطريقة الكشف بالفيديو إيدج. و تم قياس 
الموجودة داخل الخاليا   +2
 (.fura-2 AMمؤشر فلوريسنت ) باستخدام
تسبب في انخفاض ملحوظ في سعة انقباض الخاليا  (μM 1)الكانابيديول أهم نتائج هذه الدراسة هو أن 
العابر المثار بالكافيين و معدل  +Ca2. غير أن ال (Ca2+ transients)العابر  +Ca2العضلية المثارة كهربياً و 
الكانابيديول على التالية لعملية إضافة الكافيين لم تتغير. و تم التحقق من تأثير  العابر المثار كهربيا +Ca2إنعاش ال 
باالستعانة  بتقتية االلتقاط الرقعي لكامل   +L- type Ca2( و قنوات ال action potentialsخصائص جهد الفعل )
أدى إلنخفاض  (μM 1)يول الكانابيد(. باإلضافة إلى ذلك، دلت النتائج أن Whole-cell patch-clampالخلية )
الكانابيديول يمنع بينت أن   +L- type Ca2ملحوظ في المدة الزمنية لجهد الفعل. مزيد من الدراسات على قنوات ال 
 (.voltage-independent mannerبطريقة الجهد المستقلة ) μM 0.1من  IC50هذه القنوات ب 
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Glossary 
 
THC Tetrahydrocannabinol 
CBN Cannabinol 
CBD Cannabidiol 
THCA Tetrahydrocannabinolic Acid 
CBGA Cannabigerolic Acid 
CBG Cannabigerol 
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CBC Cannabichromene 
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2-AG 2-Arachidonylglycerol 
FAAH Fatty Acid Amidehydrolase 
MAGL Monoacylglycerol 
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TRPV1 Transient Vanniloid Aeceptors 1 
PPARγ Peroxisome Proliferator Activated Receptor 
VR1 Vannilloid Receptors 
PLC Phospholipase C 
PKC Phosphokinase C 
NADA N-arachidonoyl-Dopamine 
NCX Soduim- Calcium Exchanger 
APD Action Potential Duration 
RyRs  Ryanodine Receptors 
PKA Protein Kinase A 
ADP Adenosine Diphosphate 
ATP Adenosine Triphosphate 
NT Normal Tyrode 
RCL Resting Cell Length 
SR Sarcoplasmic Reticulum 
TTX Tetrodotoxin 
AMP Amplitudes 
RU Ratio Unit 
SSA Steady-State Activation 
SSL Steady-State Inactivation 
AP Action Potential 
APD Action Potential Duration 
  
 
 
 
Chapter 1: Introduction 
1.1 Aims and Objectives: 
The aims of this research are to examine the therapeutic potential and mechanism 
by which the phytocannabinoid Cannabidiol CBD affects cardiac contractility. This will 
be achieved by investigating the effects of CBD on action potential duration, ventricular 
shortening, myofilament sensitivity, and L-type calcium current. 
 
 
1.2 History 
Marijuana is a crude preparation of flowering tops, leaves, seeds and stems from 
female Indian hemp cannabis sativa plants (Figure 1). It has been used for centuries for 
both recreational and therapeutic purposes. Currently cannabis is being investigated for 
the treatment of various pathological conditions such as pain, nausea, vomiting and 
cancer. It is one of the most extensively studied plants. There were more than 12,000 
PubMed articles published in January 2014 using the key word cannabis in relation to the 
various biological and pharmacological effects of this drug.  
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Figure 1. Cannabis Sativa Leaves.ScienceDaily, n.d. Web. 30 Apr. 2014 
Figure 2. Major Phytocannabinoids 
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The medicinal use of marijuana has a long history of therapeutic use, going back 
several thousands of years. It was often used for the same medical conditions it is used to 
treat today such as muscle spasms, pain, nausea, vomiting, epilepsy, and glaucoma. 
However, use of marijuana is also associated with distorted perception (sights, sounds, 
time and touch), panic attacks, trouble with thinking, difficulties in learning and problem 
solving, and loss of motor coordination. Due to these adverse effects, the use of 
marijuana was banned in the U.S.A and throughout most of the world almost eighty years 
ago.   
During the second half of the 20
th
 century, researchers discovered that the 
biological actions of marijuana are mediated mainly by a group of chemicals collectively 
called cannabinoids. Although cannabis plant extracts contain more than 460 compounds, 
based  on  pharmacological  properties  and  radioligand binding studies,  currently  about  
60  of  the  compounds  found  in  this  plant,  are collectively named phytocannabinoids. 
Among these phytocannabinoids, Δ
9
-Tetrahydrocannabinol (THC) is a major chemical 
that mediates the psychoactive actions of the cannabis plant (Figure 2). In addition to 
THC, other cannabinoids such as Cannabigerol, Cannabichromene, Cannabinol (CBN) 
and Cannabidiol (CBD), constitute major non-psychoactive components of the cannabis 
plant. These compounds are highly lipophilic and bear significant similarities in their 
chemical structure. For example, CBD which is the focus of this study, is a structural 
isomer of THC i.e. it has the same chemical composition but the atoms are arranged 
differently.      
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While the majority of the adverse psychological effects of marijuana are known to 
be mediated by THC, the contribution of other cannabinoids such as CBD and CBN to 
the overall influence of marijuana remains unknown. In recent years, various 
combinations of these psychoactive and non-psychoactive cannabinoids have been used 
in cannabis based treatments. Different extracts of cannabis have been used 
therapeutically to relieve, asthma, pain, whooping cough, epilepsy and inflammation. 
However, due to the psychoactive effects of cannabis such as anxiety, cognitive 
impairment and hallucinations, medicinal use of these compounds was discontinued 
(Robson, 2001).   
Nevertheless, its therapeutic potential to solve a myriad of medical problems has 
attracted considerable research interest. Thus, in recent years research has focused on   
the therapeutic potential of the plant to develop new chemicals that retain the therapeutic 
benefits without causing psychotropic effects. 
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Figure 3. Illustrating Major Phytocannabinoids Synthetic Pathways. 
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1.3 Cannabinoids 
 Despite its use for centuries, the active ingredients and chemical constituents  
 Of the cannabis plant remained largely unknown until the beginning of the 1960s when 
the  main psychoactive constituent, THC was extracted and identified (Mechoulam & 
Gaoni, 1965). In the 1980s, other compounds with chemical structures similar to that of 
THC were synthesized by various drug companies in an attempt to discover new drugs to 
alleviate pain. Some of these newly synthesized compounds such  as  CP55,940, 
CP55,244, HU-210, JWH-018 displaced radioactively labeled THC in radioligand 
binding experiments and lead  to  the  discovery  of  the  first  cannabinoid receptor  
(CB1)  in  the  brain (Herkenham et al., 1990). In the 1990’s CB1 and CB2 receptors 
were cloned, expressed functionally and identified pharmacologically (Pertwee, 1997).  
Further studies in this field, indicated that, similar to opioids, there are 
endogenous ligands that can bind and activate cannabinoid receptors. These findings 
eventually lead to the discovery of “endocannabinoids” i.e. endogenously produced 
cannabinoids. Endocannabinoids mainly N-arachidonoylethanolamine (Anandamide; 
AEA) and 2-arachidonylglycerol (2-AG) have considerable agonistic effects on the 
cannabinoid receptors (Mechoulam et al., 1995), and mimic most of the pharmacological 
actions of THC. 
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1.3.1 Phytocannabinoids 
As mentioned earlier the most abundant constituents of the cannabis plant are 
THC and CBD. Within the plant, phytocannabinoids are synthesized from fatty acid 
precursors via a series of transferase and synthase enzymes (Figure 3). The two major 
phytocannabinoids, THC and CBD, are derived from a common synthetic precursor, 
cannabigerol. From a pharmaco-chemical perspective, whilst THC and CBD have pentyl 
side chains, major homologues are Δ9-tetrahydrocannabivarinand cannabidivarin, 
respectively, with propyl side chains, derived from cannabigerovarin. Importantly, 
despite only small differences in chemical structure, these compounds appear to exhibit 
markedly different pharmacological properties (Hill, Williams, Whalley, & Stephens, 
2012). 
THC has a wide spectrum of pharmacological effects ranging from anti-
inflammatory and analgesic actions to cancer treatment, mainly through the activation of 
the cannabinoid receptors (Mechoulam, Parker, & Gallily, 2002).  However, CBD has no 
agonistic activity on cannabinoid receptors, but it is capable of producing various 
pharmacological effects by acting on diverse groups of target proteins ranging from 
enzymes and receptors to neurotransmitter transporters and ion channels  (Hill et al., 
2012).  
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1.3.2 Endocannabinoids 
Endogenous ligands for the cannabinoid receptor are synthesized from 
polyunsaturated fatty acids and fatty acid derivatives from glycerol. They mimic the 
actions of phytocannabinoids by binding to cannabinoid receptors (Di Marzo, 2008). In 
addition to AEA and 2-AG, other endocannabinoids with similar fatty acid-based 
chemical structures have also been identified in the last decade (Pertwee et al., 2010). 
Some of these endocannabinoids include 2-arachidonylglycerol ether (Noladin ether); 
(Hanus et al., 2001), NADA, and virodhamine (Pertwee et al., 2010; Porter et al., 2002). 
Endocannabinoids, unlike neurotransmitters, are neither synthesized nor stored in 
the neurons. Therefore they are not released by a synaptic process, but produced in 
response to cellular activity (Di Marzo et al., 1994). It has been shown that biological 
processes such as membrane depolarization and activation of metabotropic receptors 
cause increases in intracellular Ca
2+
levels and activate enzymes involved in the synthesis 
of endocannabinoids (Di Marzo, 2008). Following their synthesis, AEA and 2-AG are 
degraded by enzymatic hydrolysis by fatty acid amide hydrolase (FAAH) and  
monoacylglycerol lipase (MAGL), respectively (Cravatt & Lichtman, 2002). 
Endocannabinoids can also be transported out of the cell by diffusion through cell 
membranes or by a mechanism that involves an unidentified transporting protein located 
in the plasma membrane (Cravatt & Lichtman, 2002; Glaser, Kaczocha, and Deutsch, 
2005).  
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1.3.3 Synthetic Cannabinoids 
Following the discovery of cannabinoid receptors there have been attempts to 
produce compounds with therapeutic effects such as anti-inflammatory/analgesic and 
anti-emetic effects without inducing the psychotropic effects. As a result various 
chemicals such as CP55,940, CP55,244,HU-210, JWH-018, and JWH-073 have been 
synthesized (Huffman et al., 1998). These compounds are known collectively as synthetic 
cannabinoids (Ashton, 2012). Currently, little is known about the biological activities of 
these compounds with their diverse chemical structures. However, recent reports indicate 
that various combinations of synthetic cannabinoids are employed for recreational 
purposes throughout the world in order to avoid legal regulations related to 
phytocannabinoids (Burstein and Zurier, 2009). However, the synthetic cannabinoid 
Nabilone has recently been approved by the FDA (U.S Food and Drug Administration) 
and recommended for the treatment of chemotherapy-induced nausea and vomiting that is 
unresponsive to conventional antiemetics (Ware, Daeninck, and Maida, 2008).In addition 
nabilone is used for the treatment of anorexia and weight loss in AIDS patients (Burstein 
and Zurier, 2009; Pertwee et al., 2010). Nabilone has also been reported to be an effective 
pain killer for patients with fibromyalgia (Skrabek, Galimova, Ethans, & Perry, 2008).  
Currently the following cannabinoid based medications have been approved by 
the FDA and are commercially available (Schicho & Storr, 2011): 1– Sativex® (GW 
Pharmaceuticals), for pain and spasticity in patients with multiple sclerosis. Currently, 
four different formulations of Sativex® are under investigation,  including  the  high  
THC  extract  (Tetranabinex®),  THC:CBD  (narrow  ratio),  THC:CBD  (broad  ratio)  
and  the  high  CBD  extract  (Nabidiolex®)  (Scuderi et  al.  2009). currently, three 
10 
 
 
 
Sativex® delivery systems exist: the oromucosal spray, sublingual tablets and inhaled 
dosage forms.  In 2005, the oromucosal spray administration of Sativex® was approved 
for the treatment of multiple sclerosis symptoms (Perras 2005). To date, Sativex 
preparations have been licensed in Canada, the UK and Spain. 2– Marinol® (Solvay 
Pharmaceuticals, Belgium), oral capsules containing dronabinol (a synthetic THC), are 
recommended as an appetite stimulant and antiemetic.  3– Cesamet® (Valeant 
Pharmaceuticals International), is an oral capsule containing nabilone (a synthetic THC 
analog), for patients with chemotherapy-induced nausea and vomiting.  This drug is 
currently licensed in Canada, the USA and the UK. 
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Table 1. Class of Cannabinoids 
Major Class Name  Action of CB 
Receptors 
Phytocannabinoids ∆9 Tetrahydrocannabinol (∆9 THC) Non selective CB1/CB2 
agonist 
Cannabigerol (CBG)  CB1 selective 
antagonist 
Cannabidiol  (CBD ) CB1 antagonist 
CB2 inverse agonist 
Cannabichromene (CBC) No action on CBRs 
Cannabinol  (CBN) Non selective CB1/CB2 
agonist 
Endocannabinoids 2-Arachidonylethanol Amide 
(Anandamide) 
Non selective CB1/CB2 
agonist 
2-Arachidonylglycerol (2-AG) Non selective CB1/CB2 
agonist 
O-Arachidonylethanolamine 
(Virodamine) 
Non selective CB1/CB2 
agonist 
12 
 
 
 
Synthetic 
Cannabinoids 
CP55,940 Non selective CB1/CB2 
agonist 
WIN55,212 Non selective CB1/CB2 
agonist 
Sch.336 CB2 selective 
Ajulemic acid (AJA) Non selective CB1/CB2 
agonist 
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1.4 Cannabidiol 
CBD is the main non-psychoactive component of cannabis and constitutes up to 
40% of cannabis extracts (Grlic, 1962). It was first isolated in 1940 and its chemical 
structure was identified in 1963 (Mechoulam and Hanus, 2002). In recent years, CBD has 
been considered to be a promising therapeutic agent for clinical use, since, in addition to 
its non-psychotropic properties, it exhibits as well as low toxicity in humans and has a 
high therapeutic index and a low teratogenic potential (Rosenkrantz, Fleischman, and 
Grant, 1981; Campos, Moreira, Gomes, Del Bel, and Guimaraes, 2012; Scuderi et al., 
2009). An orally-administered liquid containing CBD has received orphan drug status in 
the US, for use as a treatment for Dravet Syndrome, a rare-form of epilepsy that is 
resistant to treatment with current anti-epileptic drugs (Gloss, Nolan, and Staba, 2014). 
Cannabidiol is insoluble in water but soluble in organic solvents, such as DMSO 
and alcohol. It is rapidly distributed when administered intravenously, easily passes the 
blood-brain barrier and has a prolonged elimination from the body (Samara, Bialer and 
Harvey, 1990). 
 
1.4.1 Mechanisms of Action of Cannabidiol 
In general, CBD has been shown to act on a wide range of molecular and cellular 
target sites. Some of these molecular targets are various types of membrane receptors 
such as GPR55 (Ryberg et al., 2007), opioid (Kathmann, Flau, Redmer, Trankle and 
Schlicker, 2006) and 5HT1A receptors as well as Transient Vanniloid receptors 1 
(TRPV1) (Bisogno et al., 2001), and Peroxisome Proliferator Activated Receptor 
(PPARγ) (Bishop-Bailey, 2000). Significantly, CBD, at low µM concentrations acts as an 
antagonist for CB1 and CB2 receptors (Pertwee, Ross, Craib and Thomas, 2002). Other 
14 
 
 
 
proteins that CBD interacts with include voltage-gated and ligand-gated ion channels, and 
various types of enzymes (for review see Pertwee, 2008; Izzo et al., 2009; Campos et al., 
2012;Garcia-Arencibia et al., 2007). These cellular and molecular targets are discussed in 
detail in the following sections. 
a. Actions of cannabidiol on the cannabinoid system: 
In earlier clinical studies, CBD, with no detectable activity by itself, was reported 
to attenuate some of the effects of THC such as anxiety and tachycardia (Karniol, 
Shirakawa, Kasinski, Pfeferman and Carlini, 1974). Similarly, it was found that the 
pharmacological actions of cannabinoid receptor agonists can be antagonized by low (nM 
range) concentrations of CBD in a mouse’s vas deferens (Pertwee et al., 2002). These 
effects of CBD are unlikely to involve direct interaction at cannabinoid receptor CB1 and 
CB2 binding sites except at high concentrations of CBD, since CBD appears to have a 
relatively low affinity for cannabinoid receptors. Ki values for CBD-induced 
displacement of a radiolabelled ligand from cannabinoid CB1 and CB2 receptor binding 
sites have been reported to be 4.35 and 2.86 µM, respectively in one study (Showalter, 
Compton, Martin and Abood, 1996) and >10 µM in other experiments (Devane, Dysarz, 
Johnson, Melvin and Howlett, 1988; Bisogno et al., 2001). Further studies indicated that 
CBD behaves as a high-potency antagonist for cannabinoid receptor agonists in a 
mouse’s brain tissue and in membranes from CHO cells transfected with cannabinoid 
receptors (Thomas et al., 2007). It was also reported that the function of a novel receptor 
GPR55 is inhibited by low concentrations of CBD (Ryberg et al., 2007). 
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The interaction of CBD with the cannabinoid system is not limited to cannabinoid 
receptors. Tissue levels of endogenously produced cannabinoids are also affected by 
CBD. For example, it has been shown that CBD inhibits the uptake and the enzymatic 
hydrolysis of AEA (Bisogno et al., 2001). Furthermore, CBD has been shown to cause 
activation of cannabinoid receptors indirectly by enhancing tissue concentrations of 
endocannabinoids (Fowler, 2004). In functional experiments it has been suggested that 
some of the effects of CBD sensitive to CB receptor antagonists are mediated by an 
entourage effect of CBD on tissue levels of endocannabinoids (Fowler, 2004). 
b. Effects of cannabidiol on other membrane receptors: 
CBD has been shown to stimulate Vanilloid Receptors (VR1) with an efficacy 
comparable  to that of capsaicin, the natural agonist of this receptor (Bisogno et al., 
2001). The stimulation of the VR1 receptor by capsaicin and some of its analogues leads 
to fast desensitization, with subsequent analgesic and anti-inflammatory effects. It has 
been suggested that, similar to capsaicin, CBD also causes desensitization of VR1 and 
enhances the effect of capsaicin on VR1, suggesting that CBD exerts its anti-
inflammatory actions, in part, by desensitization of sensory nociceptors (Bisogno et al., 
2001).CBD has been reported to act as a weak agonist (EC50 = 3.5 µM) on human 
TRPV1 receptors inHEK293 cells expressing these receptors (De Petrocellis et al., 2011). 
CBD has also been demonstrated to act as an agonist on TRPV2 (Qin et al., 2008) and 
TRPA1 receptors, while it acts as an antagonist on the TRPM8 receptor (De Petrocellis et 
al., 2008). 
It was also shown that at a µM concentration range, CBD displaces the 8-OH-
DPAT, 5-HT1A receptor agonist, from cloned human 5-HT1A receptors expressed in 
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cultured cells obtained from a Chinese hamster ovary (E. B. Russo, Burnett, Hall and 
Parker, 2005). In subsequent studies, results of several in vivo experiments have 
supported the involvement of 5-HT1A receptors in the effect of CBD (Campos et al., 
2012). At high µM concentrations (10-100 µM), CBD has also been shown to interact 
with other G-protein coupled receptors such as 5HT2 and opioid receptors in an allosteric 
manner (E. B. Russo et al., 2005; Kathmann, et al., 2006). 
c. Effect of cannabidiol on second messengers: 
Calcium is considered one of the most important second messengers involved in 
the regulation of various cell functions, such as muscle contraction and the release of 
neurotransmitters. It has been shown that CBD treatment increases intracellular 
concentrations of Ca
2+
 in cultured hippocampus neurons (Drysdale, Ryan, Pertwee and 
Platt, 2006; Ryan, Drysdale, Lafourcade, Pertwee and Platt, 2009). In another study, the 
anti-epileptic activity of CBD has been suggested to be due to its bidirectional regulatory 
role on intracellular Ca
2+
 levels (Ryan et al., 2009). In another investigation, it was 
proposed that CBD increases intracellular Ca
2+
 levels under normal physiological 
conditions, but decreases Ca
2+ 
levels under highly excitable conditions (Mato, Victoria 
Sanchez-Gomez and Matute, 2010; Rao and Kaminski, 2006). This action of CBD was 
believed to be due to the regulation of Ca
2+
 transport in mitochondria which acts as a sink 
for intracellular Ca
2+ 
(Ryan et al., 2009). 
In addition to its influence on intracellular stores, CBD also acts on active Ca
2+
 
transport proteins such as Ca
2+
-ATPase in myocytes (Gilbert, Pertwee and Wyllie, 1977) 
and neurons (Gilbert et al., 1977; Ryan et al., 2009). The highly lipophilic nature of CBD 
grants it easy access to intracellular targets such as cellular organelles (endoplasmic 
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reticulum and  mitochondria) and intracellularly located enzymes that contribute to CBD-
induced alterations in intracellular Ca
2+ 
levels (Collins and Haavik, 1979).In this context, 
it is important to note that, the functions of various Ca
2+
-activated  enzymes  such as 
phospholipase C (PLC) (Howlett, Scott and Wilken, 1989),  phospholipaseA2, 
lipoxygenase (Takeda, Usami, Yamamoto and Watanabe, 2009) and Phosphokinase C 
(PKC) (Hillard and Auchampach, 1994; White and Tansik, 1980) are also modulated by 
low µM concentrations of CBD. 
In addition to Ca
2+
, CBD acts on the uptake process of several neurotransmitters 
(for a review see Pertwee 2008). CBD decreases the uptake of [
3
H] adenosine in both 
murine microglia and macrophages, and binding studies show that CBD binds to the 
nucleoside transporter (Carrier, Auchampach and Hillard, 2006). The enhancement of 
adenosine signaling through inhibition of its uptake was suggested as providing non-
cannabinoid receptor mechanism by which CBD can decrease inflammation (Carrier et 
al., 2006). 
d. Cannabidiol effects on voltage-gated ion channels: 
Earlier studies of motor neurons showed that CBD depresses the amplitude of 
action potential suggesting that it inhibits the function of neuronal voltage-gated Na
+
 
channels (Turkanis and Karler, 1986). However, there has been no further study 
investigating the effect of CBD on Na
+
 channels. Another study indicated that CBD 
increased the L-type Ca
2+
 current recorded in the hippocampal neurons (Drysdale et al., 
2006). Similarly to these Na
+
 channels, there have been no further studies investigating 
the actions of CBD on L-type Ca
2+
 channels. On the other hand, the effect of CBD on T-
type voltage-gated Ca
2+
 channels has been investigated in recent years. It has been shown 
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that CBD inhibits different subtypes of CaV3 family channels (Ross, Napier and Connor, 
2008). 
e. Cannabidiol effects on ligand-gated ion channels: 
In HEK-293 cells expressing glycine receptors, CBD showed a positive allosteric 
modulatory effect in a low µM concentration range (Ahrens et al., 2009). The EC50 
values for the potentiating effects of CBD were 12.3 µM for α1 and 18.1 µM for α1β1 
subunit combinations. Direct activation of glycine receptors was also observed at CBD 
concentrations above 100 µM. Similarly, glycine-mediated currents recorded in dorsal 
horn neurons of rat spinal cord slices were potentiated by CBD applications (Xiong et al., 
2012). Further investigations indicated that mutations of the α1 subunit TM2 serine 
residue to isoleucine abolished the co-activation and the direct activation, of the glycine 
receptor by CBD (Foadi et al., 2010). In in vivo experiments, it has been shown that 
systemic and intrathecal administration of CBD significantly suppressed chronic 
inflammatory and neuropathic pain without causing apparent analgesic tolerance in 
rodents (Xiong et al., 2012). The analgesic potency of CBD and 11, similarly structured 
cannabinoids, is positively correlated with potentiation of the α3-subunitglycine receptor. 
In contrast, analgesia induced by these cannabinoids is neither correlated with their 
binding affinity for CB1 and CB2 receptors nor with their psychoactive side effects. 
Furthermore, NMR analysis revealed a direct interaction between CBD and S296 in the 
third transmembrane domain of purified α3 GlyR. More importantly, the CBD-induced 
analgesic effect was absent in mice lacking the α3 subunit from the glycine receptor 
suggesting that the α3 subunit mediates glycinergic CBD-induced suppression of chronic 
pain (Xiong et al., 2012). 
19 
 
 
 
Another ligand-gated ion channel reported to be modulated by CBD is the α7-
nicotinic cholinergic receptor (Mahgoub et al., 2013). It was shown that the function of 
human α7-nicotinic receptors expressed in xenopus oocytes was inhibited by CBD with 
an IC50 value of 11.3 µM in a non-competitive manner. Significantly, the 5-HT3 
receptor, with structural similarities to the α7-nicotinic receptor was also shown to be 
inhibited in xenopus oocytes and HEK-293 cells in an allosteric manner (K. H. Yang et 
al., 2010).  
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1.4.2 Clinical Applications 
a. Anti-inflammatory actions 
 As the most abundant non-psychoactive cannabinoid in the plant, the anti-
inflammatory actions of CBD and its analogs have been studied extensively in recent 
years (Burstein and Zurier, 2009; Booz, 2011). CBD reduces joint inflammation in 
collagen-induced arthritis in mice (Sumariwalla et al., 2004) and carrageenan paw edema 
in rats (Costa et al., 2004). In addition, oral administration of CBD (2.5–20 mg/kg) 
reduces neuropathic and inflammatory pain in rats. This effect is reversed by vanilloid 
but not by CB receptor antagonists (Costa, Trovato, Comelli, Giagnoni and Colleoni, 
2007). CBD also reduces intestinal inflammation in mice (Capasso et al., 2008). In 
addition to its ability to suppress production of the inflammatory cytokine TNFα, CBD 
appears to exert anti-inflammatory pressure by suppressing the fatty acid amidohydrolase 
(FAAH), thereby increasing concentrations of the anti-inflammatory endocannabinoid 
anandamide. Further, insight into mechanisms whereby CBD exerts therapeutic effects 
was provided by experiments which indicated that CBD attenuates inflammation induced 
by high glucose levels in diabetic mice (Rajesh et al., 2007). Specifically, CBD treatment 
reduces mitochondrial superoxide, inducible nitric oxide synthase, nuclear factor kappa β 
activation, and transendothelial migration of monocytes (Burstein and Zurier, 2009; 
Booz, 2011).Another potential therapeutic use of CBD may lie in its ability to counter 
some undesirable effects of THC (sedation, psychotropic effects, tachycardia), thus 
suggesting that if given together with THC, it may allow higher doses of THC (E. Russo 
& Guy, 2006). THC and CBD have been administered as an oral mucosal spray to 58 
patients with rheumatoid arthritis (Blake, Robson, Ho, Jubb and McCabe, 2006). Treated 
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patients had a significant reduction in pain and an improvement in sleep compared to 
patients given a placebo. 
b. Neuroprotection 
In earlier studies, CBD has been shown to normalize glutamate homeostasis 
(Hampson et al., 2000; El-Remessy et al., 2003), reduce oxidative stress (Hampson, 
Grimaldi, Axelrod and Wink, 1998; Marsicano, Moosmann, Hermann, Lutz, and Behl, 
2002), attenuate glial activation and the occurrence of local inflammatory events (Ruiz-
Valdepenas et al., 2011; Martin-Moreno et al., 2011). It appears that there may be two 
key mechanisms underlying the neuroprotective effects of CBD. The first is the 
capability of CBD to restore the normal balance between oxidative events and antioxidant 
endogenous mechanisms (Fernandez-Ruiz, 2012) that are frequently disrupted in 
neurodegenerative disorders, thereby enhancing neuronal survival. The second is CBD as 
a neuroprotective compound, and its anti-inflammatory activity. The anti-inflammatory 
effects of CBD are related to the control of microglial cell migration and the toxicity 
exerted by these cells, i.e.the production of pro-inflammatory mediators (Fernandez-Ruiz, 
2012). 
The neuroprotective effects of CBD were also evaluated in animal models with 
Parkinson’s disease, Huntington’s disease and neonatal ischemia. Pathological changes 
induced by 6-hydroxydopamine, a toxic compound that targets catecholaminergic cells, 
were significantly reduced by CBD treatment (Lastres-Becker, Molina-Holgado, Ramos, 
Mechoulam and Fernandez-Ruiz, 2005; Mechoulam, et al., 2002). It appears that these 
reductions after CBD treatment were irreversible, as they did not recover when CBD was 
halted (Mechoulam, Peters, Murillo-Rodriguez and Hanus, 2007). CBD was also useful 
22 
 
 
 
in preventing beta-amyloid–induced neurodegeneration in in vivo and in vitro models of 
Alzheimer disease (Fernandez-Ruiz, 2012). Increased production of reactive oxygen 
species, lipid peroxidation, DNA fragmentation, and intracellular Ca
2+
 concentrations 
induced by beta-amyloid peptide were significantly reduced after CBD treatment of PC12 
cells (Iuvone et al., 2004). 
CBD has also been shown to be protective against neuronal damage due to 
ischemia (Hampson et al., 2000). In rats subjected to middle cerebral artery occlusion, 
infarct size and neurological impairment were reduced by 50-60% by CBD. Similarly, 
post-ischemic administration of CBD protected against hyperlocomotion and neuronal 
injury following middle cerebral artery occlusion in gerbils (Braida et al., 2003). 
Furthermore, it was recently shown that CBD treatment reduced the infarct volume in 
brain ischemia, and that this effect was independent of cannabinoid receptor type 1and 
transient receptor potential V1, but sensitive to the 5-HT1A receptor antagonist, 
WAY100135 (Hayakawa et al., 2004; Mishima et al., 2005) suggesting that activation of 
5-HT1A receptors mediate the neuroprotective effects of CBD. 
c. Treatment of nausea and vomiting 
Cannabis has long been used to treat nausea and vomiting induced by various 
drugs and pathological conditions (Parker, Rock and Limebeer, 2011). Several 
combinations of phytocannabinoids and synthetic cannabinoids have currently been 
approved for use in the treatment of chemotherapy-induced nausea and vomiting (Parker 
et al., 2011).The reduction of nausea and vomiting demonstrated by cannabis sativa use 
in vivo and in vitro has been attributed to the presence of THC and CBD. Unlike THC, 
which exerts its action via CB1 receptors, CBD mimics the anti-nausea and anti-vomiting 
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properties of THC through mechanisms unrelated to CB receptor activation (Mechoulam 
et al., 2007). Interestingly, one of the most effective antiemetic drugs used in clinics is a 
5HT3 receptor antagonist (Thompson, Chau, Chan and Lummis, 2006). 5HT3 receptors 
belong to a superfamily of ligand-gated ion channels that mediate serotonin-induced 
rapid depolarizations in intestinal neurons and regulate peristaltic activity of intestinal 
smooth muscle (Izzo and Camilleri, 2009). CBD and THC have been shown to inhibit 
5HT3receptors (K. H. Yang et al., 2010)and suppress emesis induced by various chemical 
and physical stimuli (Parker et al., 2011). 
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d. Cardiovascular effects 
i) Anti-arrhythmic role of CBD: 
Studies examining the cardioprotective effects of CBD showed that CBD has 
antiarrythmic effects after an ischemic reperfusion injury (Walsh, Hepburn, Kane and 
Wainwright, 2010). In models of myocardial infarction following ligation of the left 
anterior descending coronary artery, in vivo treatment with CBD resulted in a reduction 
in infarct size (Rajesh et al., 2010). This finding has been attributed to an immuno-
modulatory effect in CBD, since it was accompanied by a reduction in leukocyte 
infiltration and interleukin 6 concentrations. A single dose of CBD given 10 minutes 
prior to ischemia or reperfusion resulted in a reduction in infarct size, and a significant 
reduction in the incidence of ventricular tachycardia and total number of ventricular 
ectopic beats (Stanley, Hind and O'Sullivan, 2013). 
The CB1 receptor antagonist, AM251, also demonstrates antiarrhythmic 
properties, and treatment with AM251 co-administered with CBD has a synergistic 
effect, suggesting that activation of CB1 receptors is proarrhythmic (Walsh et al., 2010). 
The synergism observed, which persists when CB1 receptors are blocked prior to CBD 
administration, is suggestive of cross talk between CB1 and other CB receptors in the 
ischemic heart (Walsh et al., 2010).Furthermore, CBD significantly reduces cardiac 
dysfunction in mice with diabetes. CBD treatment has been shown to decrease 
myocardial inflammation, reduce oxidative stress as demonstrated by a reduction in 
nuclear factor-kB activation, suppress mitogen-activated protein kinase activation, and 
reduce the expression of adhesion molecules and tumor necrosis factor (Walsh et al., 
2010). 
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ii)  Vascular effects of CBDs: 
     CBDs exert vasodilative effects as demonstrated by in vivo and in vitro models 
(see Stanley, Hind and O'Sullivan, 2013). However, the mechanism and potency of CBD 
appear to differ between various experimental models. For example, in some studies, 
CBD acts through cyclooxygenase, while other experiment use through CB1 receptor 
antagonism and the inhibition of potassium (K
+
) channel hyperpolarization. The size of 
the blood vessel is also a key factor, as maximal responses to anandamide (AEA) are 
observed in small resistance vessels (O'Sullivan, Kendall and Randall, 2005). 
In rat aorta, time-dependent CBD vasodilatation has been shown to be mediated 
through Gi/o protein that is sensitive to pertussis toxin, but is not sensitive to CB1 
antagonism or TRPV1 desensitization (O'Sullivan, Sun, Bennett, Randall and Kendall, 
2009). Additional differences are observed in other species. The mechanism by which 
vasodilatation occurs is also dependent on the type of cannabinoid. For instance, AEA 
and N-arachidonoyl-dopamine (NADA) exert similar vasodilatation effects in rat aorta; 
however, these effects occur through different mechanisms (Stanley, et al., 2013). 
It has also been demonstrated that CBD induces vasodilatation of segments of 
human mesenteric artery preconstricted with U46619 and endothelin-1. The authors of 
this study determined that mesenteric artery relaxation is endothelium-dependent, and 
involves CB1 receptor and TRPV channel activation, NO release and K
+
 channel 
hyperpolarization (Stanley et al., 2013). 
iii) Relationship between CBD and peroxisome proliferator-activated receptor 
gamma: 
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   Nuclear receptors are proteins found within cells that regulate diverse functions, 
such as homeostasis, reproduction, development, and metabolism. Peroxisome 
proliferator-activated receptor gamma (PPARγ) belongs to a family of nuclear receptors 
and plays a crucial role in glucose and lipid homeostasis, in addition to cell proliferation, 
cell differentiation, and inflammatory responses (Bishop-Bailey, 2000; Hsueh and 
Bruemmer, 2004). There is evidence to suggest that cannabinoids bind to and activate 
PPARγ, thereby causing PPAR-mediated responses. THC, which is the major component 
of cannabis, causes time-dependent endothelium-dependent and PPARγ-mediated 
vasodilatation of rat aorta. In contrast, CBD, which is a weak agonist of PPARγ 
receptors, causes increased PPARγ transcriptional activity in PPARγ-overexpressing 
HEK293 cells (Hsueh and Bruemmer, 2004). 
Since CBD is a weak PPARγ receptor agonist, side effects normally associated with 
PPARγ receptor activation, such as weight gain, edema, and increased plasma lipoprotein 
can be avoided. Therefore, CBD may prove to have therapeutic potential as a low affinity 
agonist (O'Sullivan et al., 2009; Walsh et al., 2010).  
iv) Hemodynamic effects of CBD: 
   Studies on the hemodynamic effects of CBD proved inconclusive. In some studies, 
a 16-mm Hg reduction in mean arterial blood pressure was noted, with no change in heart 
rate (Walsh et al., 2010). The authors of this study concluded that the effects of CBD are 
best seen in models with elevated blood pressure (Walsh et al., 2010). However, other 
studies did not demonstrate significant hemodynamic changes (Bergamaschi, Queiroz, 
Zuardi and Crippa, 2011).  
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CBD is reported to have anxiolytic properties, and is effective as a treatment for a 
fear of public speaking. CBD reduced heart rate and blood pressure responses in Wistar 
rats conditioned by fear. This response is believed to be mediated by 5HT1A receptors, 
since the effects were inhibited by the 5HT1A receptor antagonist, WAY100635 (Gomes, 
Resstel and Guimaraes, 2011; Zuardi, 2008). 
v) Vascular protective effects of CBD: 
High glucose levels are known to contribute to endothelial dysfunction in patients 
with diabetes. High glucose levels promote the inhibition of endothelial NO, decrease the 
vasodilatation effects and increase the vasoconstrictor effects of prostanoids, increase 
superoxide production, and increase ROS production (Vanhoutte, Shimokawa, Tang and 
Feletou, 2009). The aforementioned effects of high glucose were reduced when cells 
were co-incubated with CBD (Rajesh et al., 2007). Key elements of atherosclerosis, such 
as monocyte adhesion and transendothelial lmigration are reduced by CBD. Neither CB1 
nor CB2 receptors appear to be responsible for mediating these effects of CBD (Rajesh et 
al., 2007). Treatment with CBD may also protect against diabetic retinopathy. CBD 
prevented vascular hyperpermeability at the blood-retinal barrier (BRB), and protected 
the retina against oxidative damage, inflammation, and increased levels of cell adhesion 
molecules in an in vivo model of diabetic retinopathy (El-Remessy et al., 2006). 
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1.5 Contraction of Cardiac Muscle 
Contraction of cardiac muscle cells or cardiomyocytes shows certain characteristics 
specific to this muscle. For example, contraction of cardiomyocytes is not initiated by 
neurons as in skeletal muscle but by electrical excitation originating from the heart’s own 
pacemaker, the sinoatrial node, which generates spontaneous and periodic action 
potentials. When an action potential is initiated in one cell, current flows through the gap 
junctions and depolarizes neighboring cells. If depolarization causes the membrane 
potential to be more positive than the threshold, self-propagating action potentials occur 
in the neighboring cells as well. Thus, the generation of an action potential is just as 
critical for initiating contraction in cardiac muscle as it is in skeletal muscle, but it is 
triggered by the sinoatrial node and the specialized conduction system of the heart 
(Figure 4). 
Figure 4. Anatomy and Function of the Heart's 
Electrical System. Johns Hopkins Medicine, 
Baltimore, Maryland. 
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Separate tubular structures, the transverse tubules (T tubules), cross the cell. In the 
cardiac myocyte, the T tubule crossings occur at the Z-line, in contrast to the A-I junction 
in skeletal muscle. The lumen of the T tubule is continuous with the extracellular fluid 
surrounding the cell and, as in skeletal muscles, the action potential is propagated down 
the T tubule (Ferrantini et al., 2013). Adjacent cardiac myocytes are joined end-to-end at 
structures known as intercalated disks. These always occur at a Z-line (Figure 5). At these 
points, the cell membranes form a number of parallel folds and are tightly held together 
by desmosomes. This results in strong cell-to-cell cohesion, thus allowing the contraction 
of one myocyte to be transmitted axially to the next. Gap junctions exist between cardiac 
muscle cells, providing low resistance pathways for the spread of excitation from one cell 
to another. 
 
Figure 5. Adjacent cardiac myocytes are joined end-to-end at 
structures known as intercalated disks. 
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Figure 6. Ventricular action potential membrane currents that generate a 
normal action potential. Resting (4), upstroke (0), early repolarization (1), pla- 
teau (2) and final repolarization are the 5 phases of the action potential. A decline of 
potential at the end of phase 3 in pacemaker cells, such as the sinus node, is shown as 
a broken line. The inward currents, INa, ICa and If, are shown in yellow boxes; the 
sodium-calcium exchanger (NCX) is also shown in yellow. It is electrogenic and may 
generate inward or outward current. IKAch, IK1, Ito, IKur, IKr, and IKs are shown in 
gray boxes. The action potential duration (APD) is approximately 200 ms (Nattel & 
Carlsson, 2006). 
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1.5.1 Excitation–Contraction Coupling 
a. The ventricular action potential  
The cardiac action potential represents changes in the membrane potential due to 
the movement of ions across the cell membrane through voltage-gated ion channels, 
pumps, and exchangers, and has distinct characteristics in different regions of the heart. 
In ventricular cardiomyocytes (Amin, Tan and Wilde, 2010). According to kinetic 
properties, the cardiac action potential is divided into 4 distinct phases (Figure 6). The 
first phase of the action potential is characterized by the activation of fast Na
+
 channels, 
which open briefly to produce an influx of positive Na
+
 ions causing rapid depolarization 
of the cell membrane and an upstroke of the action potential. This initial phase is called 
phase 0. Following phase 0, a brief repolarization is observed at the peak of the action 
potential and is the consequence of both fast Na
+
 channel inactivation and the activation 
of initial repolarizing currents. This brief repolarization phase is called phase 1. 
Following phase 1, a long lasting plateau of depolarization (100-200 ms), named phase 2, 
is observed. Depolarizing currents, mainly late Na
+
 and L-type Ca
2+
 channels stay open 
and continue to offset repolarizing currents during the plateau phase. Finally, L-type Ca
2+
 
channels begin to inactivate and several cardiac K
+
 channels such as delayed-rectifier and 
inward-rectifier K
+
 channels begin to open and cause the repolarization of the membrane 
to resting membrane potential. This repolarization is called phase 3. The ventricular 
action potential is regenerative, and continues to excite ventricular cells if the stimulus 
exceeds the critical threshold for depolarization as determined by availability of Na
+
 
current. Phase 4 is the resting membrane potential, and describes the membrane potential 
when the cardiomyocyte is not being stimulated. In a great majority of contracting 
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cardiomyocytes phase 4 has a low slope (almost a horizontal line). However, in 
pacemaking cells, phase 4 is unstable (phase 4 - is the pacemaker potential). In 
pacemaker cells (such as the Sinoatrial node), the membrane slowly depolarizes during 
phase 4, until it reaches a threshold potential (around -40mV) or until it is depolarized by 
an electrical impulse coming from another cell. The reason for this pacemaker potential is 
an increased inward current of sodium (Na
+
) through voltage-dependent channels, but 
also an increased inward Ca
2+
 current and a decrease in the K
+
 outward current. These 
Na
+
 channels, in cardiac pacemaker cells, contrary to what usually happens in other cells, 
open when the voltage is more negative. 
b. Calcium-induced calcium release 
          The action potential propagates along the sarcolemma, invades the transverse 
tubules and causes release of Ca
2+
 from internal Ca
2+
 stores such as sarcoplasmic 
reticulum and leads eventually to the initiation of muscle contraction. This sequence of 
events, beginning with action potential generation and resulting in muscle contraction is 
known as excitation-contraction coupling (Figure 7). Initially, depolarization caused by 
the action potential activates voltage-gated L-type Ca
2+
 channels which are concentrated 
in the Tubules (Shepherd and McDonough, 1998). Activation of these channels induces a 
conformational change in the ion channel structure and causes a subsequent influx of 
Ca
2+
into the cell. This influx of Ca
2+
 is known as sparklets (Navedo and Santana, 2013). 
The presence of sparklets is not sufficient to cause activation of the contractile 
machinery. However, it is sufficient to initiate the release of furtherCa
2+
from intracellular 
stores by interacting with ryanodine receptors (RyRs) on the sarcoplasmic reticulum. The 
local amplification of intracellular Ca
2+
 mediated by RyR activation is also known as a 
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Ca
2+
spark (Fearnley, Roderick and Bootman, 2011), and is essential for causing a Ca
2+
 
transient that activates the contractile myofilaments resulting in muscle contraction. In 
general, cytosolic Ca
2+
 influx in ventricular cells occurs mainly through two distinct 
sources. About 8 to 23% of Ca
2+
 enters extracellularly through the opening of L-type 
Ca
2+
 channels and 77% to 92% of total Ca
2+
 employed in muscle contraction is released 
from the sarcoplasmic reticulum through RyRs, although some inter-species differences 
do exist (Bers, 2008). The contribution of NCX and mitochondria to cytosolic Ca
2+
 is 
usually not more than 1% (Bers, 2000). Following its release, Ca
2+
 is pumped back into 
the sarcoplasmic reticulum by a Ca
2+
-ATPase pump and also removed from the cell via 
the Na
+
/Ca
2+
 exchanger located at the plasma membrane (Wang, Song, Lakatta and 
Cheng, 2001).In cardiac muscle, the activity of a Ca
2+
-ATPase in the sarcoplasmic 
reticulum is inhibited by the regulatory protein phospholamban. When phospholamban is 
phosphorylated by cAMP-dependent protein kinase, its ability to inhibit the Ca
2+
-ATPase 
is lost. Thus, activators of cAMP-dependent protein kinase, such as the neurotransmitter 
epinephrine, may enhance the rate of cardiac myocyte relaxation. 
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Figure 7.  Cardiac excitation contraction coupling. Inset shows the time course of an action 
potential, Ca
2+
 transient and contraction measured in a rabbit ventricular myocyte at 37 °C. NCX, 
Na
+
/Ca
2+
 exchange; ATP, ATPase; PLB, phospholamban; SR, sarcoplasmic reticulum (Bers -
 ‎2002).
 
 
 
Calcium Channels 
Due to the importance of Ca
2+
 in various vital cellular events such as muscle 
contraction, neurotransmitter release, and exocytosis; the regulation of Ca
2+
 entrance 
through voltage-gated Ca
2+
 channels has been studied in detail (Catterall, Perez-Reyes, 
Snutch and Striessnig, 2005). According to pharmacological and biophysical 
characteristics three different types of Ca
2+
 channels have been characterized. These 
different types of Ca
2+
 channels are summarized in Table 2. 
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In the heart, both T-type and L-type Ca
2+
 channels have been shown to be 
expressed  (Zhou and January, 1998). However, T-type Ca
2+
 channels appear to be 
localized mainly in cells involved in heart rhythm and automaticity such as pacemaker 
and atrial cells, while L-type Ca
2+
 channels are localized mainly in ventricular myocytes. 
As mentioned above, due to their slow activation kinetics, L-type Ca
2+
 channels require 
long depolarizations lasting 100-200 ms. After the activation process, L-type Ca
2+
 
channels are inactivated by various factors which include time, voltage, cytosolic Ca
2+
 
concentration and calmodulin (Bers, 2000). 
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Table 2. Classification of calcium channels 
 
Ca
2+ 
current
type 
α1 
subunits 
Specific 
blocker 
Principal physiological functions Inherited diseases 
L Cav 1.1 DHPs Excitation-contraction coupling in 
skeletal muscle, regulation of 
transcription 
 
Hypokalemic periodic 
paralysis 
 Cav1.2 DHPs Excitation contraction coupling in 
cardiac and smooth muscle, endocrine 
secretion, neuronal Ca
2+ 
transients in 
cell bodies and dendrites, regulation of 
enzyme activity, regulation of 
transcription 
Timothy syndrome: cardiac 
arrhythmia with 
developmental abnormalities 
and autism spectrum 
disorders 
 Cav1.3 DHPs Visual transduction Stationary night blindness 
N Cav2.1 ω-CTx-GVIA Neurotransmitter release, Dendritic 
Ca
2+
 transients 
 
P/Q Cav2.2 ω-Agatoxin Neurotransmitter release, Dendritic 
Ca
2+
 transients  
Familial hemiplegic 
migraine, cerebellar ataxia  
R Cav2.3 SNX-482 Neurotransmitter release, Dendritic 
Ca
2+
 transients  
 
T Cav3.1 None Pacemaking and repetitive firing  
 Cav3.2  Pacemaking and repetitive firing Absence seizures 
 Cav3.3    
 
Abbreviations: DHP, dihydropyridine; Ѡ-CTx-GVIA, Ѡ –conotoxin GVIA from the cone snail 
Conusgeographus; SNX-482, a synthetic version of a peptide toxin from the tarantula 
Hysterocratesgigas (Catterall, 2011). 
 
As shown in Figure 8, the L-type Ca
2+
 channel consists of 4 subunits: the major 
pore-forming 1 subunit and a variety of accessory subunits. Theα1 subunit: Formed of 4 
homologous domains (I–IV), each consisting of 6 transmembrane (TM) helices joined by 
intracellular links. The loops between TM5 and TM6form the channel pore, while TM4 
contains arginine or lysine residues that form the voltage sensor, which is thought to 
move or twist as the membrane potential changes. 
Ion selectivity is governed by a glutamate residue preserved in the pore-lining 
loop of all 4 domains (Dolphin, 2006; J. Yang, Ellinor, Sather, Zhang and Tsien, 1993). 
Two Ca
2+
 ions enter the cell at a time, are regulated by 2 glutamate residues and flow 
down the Ca
2+
concentration gradient (Heinemann, Terlau, Stuhmer, Imoto and Numa, 
1992; J. Yang et al., 1993). Lanthanum, cobalt and cadmium inhibit the α1 subunit 
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(Dolphin, 2009). Expression of the α1 subunit without the auxiliary subunits, results in 
low L-type Ca
2+
 channel expression levels, and abnormal voltage and kinetic properties 
in the channel. The β subunit is located on the intracellular side of the channel. It interacts 
with the  subunit through the -interaction domain (AID), a guanylate cyclase–like 
region located between domains I and II (Catterall, 2011; Pragnell et al., 1994). The AID 
has a well-conserved gene sequence and also occurs in N-type and P/Q-type 
Ca
2+
channels (Richards, Butcher and Dolphin, 2004).The β subunit alters channel 
expression, voltage dependence, and gating kinetics. Four β subunits have been cloned, 
and all except for β2a hyperpolarize activation and steady-state inactivation of Ca
2+ 
(Dolphin, 2003). The α2δ subunit is an accessory subunit consisting of the 
transmembrane domain, and 2, an extracellular domain. Four 2 isoforms have been 
identified. Co-expression of α2δ subunits increases Ca
2+
channel expression and function. 
The  subunit is a 30 to 40kD inhibitory protein consisting of 4 TM helices (Takahashi, 
Seagar, Jones, Reber and Catterall, 1987). 
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Figure 8. Calcium channel subunits. Structure of calcium channels showing the five subunits α, 
β, α2δ and (Figure modified from Catterall, 2011).    
 
 
Secretion of catecholamines from the adrenal medulla and the autonomic nervous 
system stimulates β-adrenergic receptors via adenylcyclase, cAMP, and protein kinase A 
(PKA) to produce positive chronotropic, inotropic and lusitropic effects. Cardiac L-type 
Ca
2+
 channels are modulated through the β-adrenergic/cAMP signaling pathway; α1 and β 
subunits are phosphorylated by PKA (De Jongh et al., 1996; Haase, Bartel, Karczewski, 
Morano& Krause, 1996; Hell et al., 1993; Puri, Gerhardstein, Zhao, Ladner and Hosey, 
1997). β-adrenergic receptor activation causes a 2-fold increase in the L-type Ca
2+
 current 
by increasing the number of channels and their activation probability. The latter is 
mediated through PKA-mediated phosphorylation of the Cav1.2 (1C-subunit) channel 
protein and/or associated proteins (Catterall, 2010). As opposed to the adrenergic system, 
reciprocal control over Ca
2+
 entry is provided by ACh, acting through muscarinic Ach 
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receptors, raising intracellular cGMP concentrations and causing cGMP-dependent 
phosphorylation of the L-type Ca
2+
 channels. In turn, the cGMP-dependent 
phosphorylation of L-type Ca
2+
 channels, at sites distinct from those phosphorylated by 
the cAMP-dependent kinase, causes a decrease in Ca
2+
 influx during the cardiac action 
potential and thus a decrease in the force of contraction. 
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1.5.2 Sarcoplasmic Reticulum and Ryanodine Receptors 
The sarcoplasmic reticulum has many roles in the regulation of muscle 
contraction and intracellular Ca
2+
homeostasis. The release of Ca
2+
 from this organelle 
causes increased Ca
2+
levels to activate various Ca
2+
 dependent enzymes such as 
calmodulin and adenyl cyclase (Fearnley et al., 2011). It is also the site of phospholipid 
generation and it communicates with other intracellular organelles, such as the 
mitochondria. However, it’s most important function is the regulation of Ca
2+
 
homeostasis. It is well known that cytosolic Ca
2+
levels during resting conditions are in 
the nM range, while extracellular Ca
2+
concentrations are much higher (μM range). As 
mentioned above, following an action potential, cytosolic Ca
2+
concentration increases 
and activates ryanodine receptors, which amplify the Ca
2+
 signal and stimulate Ca
2+
-
induced Ca
2+
release. Several isoforms of ryanodine receptors (RyR) have been identified: 
RyR1 is expressed in skeletal muscle, RyR2 in cardiac muscle and the brain, and RyR3 in 
the brain (Lanner, Georgiou, Joshi and Hamilton, 2010). Although the ryanodine receptor 
is a protein of thr SR membrane, 80% of this protein is located in the cytoplasm. The 
intracellular position of ryanodine differs from one cell type to another (Zucchi and 
Ronca-Testoni, 1997). It can be directly attached (as in skeletal muscles) or detached (as 
in cardiac muscles) to the L-type Ca
2+
 channel. In skeletal muscle, direct interaction of 
the ryanodine receptor with the L-type Ca
2+
 channel causes fast excitation-contraction 
coupling and rapid initiation of skeletal muscle contraction (within a few minutes). In 
cardiac muscle on the other hand, excitation-contraction is a relatively slow process 
(within hundreds of minutes). Function of the ryanodine receptor is also regulated by 
several ligands, including Ca
2+
, calmodulin and caffeine (Fearnley et al., 2011). 
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1.5.3 The Contractile Machinery 
Myofilaments occupy about half of the cell volume in mammalian ventricular 
myocytes. As with skeletal muscle, cardiac myocytes contain the contractile proteins 
actin (thin filaments) and myosin (thick filaments) together with the regulatory proteins 
troponin and tropomyosin. In their structural configuration, the thin filament comprises 
actin with a spiraling backbone of tropomyosin, along with troponin complexes (C, I and 
T) that occur at certain intervals (Figure 9). Each actin filament consists of a site where 
myosin can bind, but these sites are blocked by tropomyosin when cytosolic Ca
2+
 
concentration is low. When cytosolic Ca
2+
 concentration increases due to Ca
2+
release, 
Ca
2+
 binds to troponin C causing tropomyosin to shift, thereby exposing the myosin 
binding sites. Adenosine diphosphate (ADP) and phosphate, present on the myosin head 
since the previous movement cycle, are released when myosin attaches to myosin binding 
sites on the actin filaments. The energy generated in the head is used to initiate upstroke 
and sliding, until the actin–myosin complex is liberated by adenosine triphosphate (ATP) 
binding the myosin head. ATP is hydrolyzed to ADP and phosphate, releasing energy 
that is stored in the myosin head to be used in the subsequent stroke. 
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Figure 9. Sarcomere structure. The thin filament is composed of actin, tropomyosin, and the 
troponin which consists of the troponins Tn-T, Tn-C, and Tn-I. The thick filament is composed of 
myosin, a globular head portion (S1), a hinged stalk region (S2) and a rod section. S1 consists of 
an ATP hydrolysis domain and the actin binding domain, it is associated with the light-chain 1 
and 2 (LC-1; LC-2) (Hamdani et al., 2008). 
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1.5.4 Calcium Sensitivity of Myofilaments 
The term myofilament Ca
2+
 sensitivity came into use after it was discovered that 
the force of contraction is not only dependent on the free cytosolic Ca
2+
 concentration, 
but also on the affinity of troponin C for Ca
2+
. Biochemical and physiological 
experiments have shown that several factors affect myofilamentCa
2+
 sensitivity, 
including pH, temperature, ionic strength and troponin I phosphorylation (Ruegg, 2003). 
Furthermore, these factors can be categorized by whether they affect thick or thin 
filaments (Bers, 2001). Factors that affect thick filaments tend to affect the relationship 
between intracellular Ca
2+
 concentration and the extent of myosin light chain 
phosphorylation. Whereas factors that affect thin filaments, affect phosphorylation of 
myosin light chain and force generation due to contractile proteins (Bers, 2001). 
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Chapter 2: Methods 
2.1 Ventricular Myocyte Isolation 
   Ventricular myocytes were isolated from adult male Wistar rats (264 ± 19 g) 
according to previously described techniques. This study was carried out in accordance 
with the recommendations in the Guide for the Care and Use of Laboratory Animals from 
the National Institutes of Health. The protocol was approved by the Committee on the 
Ethics of Animal Experiments at the United Arab Emirates University. In brief, the 
animals were euthanized using a guillotine and their hearts were removed rapidly and 
mounted for retrograde perfusion according to the Langendorff method (Figure 10). The 
hearts were perfused at a constant flow of 8 ml g heart
-1
 min
-1
 and at 36–37 °C with a 
solution containing (mM): 130 NaCl, 5.4 KCl, 1.4 MgCl2, 0.75 CaCl2, 0.4 NaH2PO4, 5 
HEPES, 10 glucose, 20 taurine and 10 creatine set to pH 7.3 with NaOH. When the heart 
had stabilized perfusion was continued for 4 minutes with a Ca
2+
-free isolation solution 
containing 0.1 mM EGTA, and then for 6 minutes with cell isolation solution containing 
0.05 mM Ca
2+
, 0.75 mg/ml collagenase (type 1; Worthington Biochemical Corp., USA) 
and 0.075 mg/ml protease (type X1V; Sigma, Germany). Ventricles were excised from 
the heart, minced and gently shaken in collagenase-containing isolation solution 
supplemented with 1% BSA. Cells were filtered from this solution at 4 minutes intervals 
and resuspended in an isolation solution containing 0.75 mM Ca
2+
. 
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Figure 10. Langendorff Heart 
  
Solution 
Chamber 
Heating 
Coil 
Water jacketed 
sugar chamber 
Peristaltic 
pump 
46 
 
 
 
2.2 Measurement of Ventricular Myocyte Shortening 
   Ventricular myocytes were allowed to settle on the glass bottom of a Perspex 
chamber mounted on the stage of an inverted microscope (Axiovert 35, Zeiss, Germany). 
Myocytes were superfused (3–5 ml/min) with normal Tyrode (NT) containing (mM): 130 
NaCl, 5 KCl, 1 MgCl2, 10 glucose, 5 HEPES, 20 taurine, 10 creatine and 0.75 CaCl2 (pH 
7.4). Shortening of myocytes was recorded using a video edge detection system (VED-
114, Crystal Biotech, USA) according to previously described techniques (Howarth, 
Qureshi and White, 2002). Resting cell length (RCL) time to peak (TPK), time to half 
(THALF) relaxation and amplitude of shortening (expressed as a percentage of resting 
cell length) were measured in electrically stimulated (1 Hz) myocytes maintained at 35–
36 °C. Data was acquired and analyzed with signal averager software v 6.37 (Cambridge 
Electronic Design, UK). Experimental solutions were prepared from stock immediately 
prior to each experiment. 
 
2.3 Measurement of Intracellular Ca2+ Concentration 
   Myocytes were loaded with the fluorescent indicator fura-2 AM (F-1221, 
Molecular Probes, USA) as described (Howarth et al., 2002). In brief, 6.25 μl of a 1 mM 
stock solution of fura-2 AM (dissolved in dimethyl sulphoxide) was added to 2.5 ml of 
cells to give a final fura-2 concentration of 2.5 μM. Myocytes were gently shaken for 
10 minutes at 24 °C (room temperature). After loading, myocytes were centrifuged, 
washed with NT to remove extracellular fura-2 and then left for 30 min to ensure 
complete hydrolysis of the intracellular ester. Intracellular Ca
2+
 was measured according 
to previously described techniques (Howarth et al., 2011). Myocytes were alternately 
illuminated by 340 and 380 nm light using a monochromator (Cairn Research, UK) 
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which changed the excitation light every 2 minutes. The resulting fluorescence emitted at 
510 nm was recorded by a photomultiplier tube and the ratio of the fluorescence emitted 
at the two excitation wavelengths (340/380 ratio) was calculated to provide an index of 
intracellular Ca
2+
 concentration. Resting fura-2 ratio, time to peak (TPK), time to half 
(THALF) decay of the Ca
2+
 transient, and the amplitude of the Ca
2+
 transient were 
measured in electrically stimulated (1 Hz) myocytes maintained at 35-36 ℃. Data were 
acquired and analyzed with signal averager software v 6.37 Cambridge Electronic 
Design, UK)  
 
2.4 Measurement of Sarcoplasmic Reticulum Ca2+ Content 
Sarcoplasmic reticulum (SR) Ca
2+
 release was assessed using previously described 
techniques (Howarth et al., 2002). After establishing a steady state of Ca
2+
 transients in 
electrically stimulated (1 Hz) myocytes maintained at 35–36 °C and loaded with fura-2, 
stimulation was paused for a period of 5 seconds (Figure 11). Caffeine (20 mM) was then 
applied for 10 seconds using a solution switching device customized for rapid solution 
exchange. Electrical stimulation was resumed and the Ca
2+
 transients were allowed to 
recover to a steady state. SR-releasable Ca
2+
 was assessed by measuring the area under 
the curve of the caffeine-evoked Ca
2+
 transient. Fractional release of SR Ca
2+
 was 
assessed by comparing the amplitude of the electrically evoked steady state 
Ca
2+
transients with that of the caffeine-evoked Ca
2+
 transient and refilling of the SR was 
assessed by measuring the rate of recovery of electrically evoked Ca
2+
 transients 
following the application of caffeine. 
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2.5 Assessment of Myofilament Sensitivity to Ca2+ 
   In some cells shortening and fura-2 ratio were recorded simultaneously. 
Myofilament sensitivity to Ca
2+
 was assessed from phase-plane diagrams of fura-2 ratio 
versus cell length by measuring the gradient of the fura-2-cell length trajectory during 
late relaxation of the twitch contraction. The position of the trajectory reflects the relative 
myofilament response to Ca
2+
 and hence, can be used as a measure of myofilament 
sensitivity to Ca
2+ 
(Spurgeon et al., 1992; Howarth et al., 2002). 
Figure 11. The recording system used for video edge detection and Ca2+ imaging 
experiments: The system includes an anti-vibration table (A), a Faraday cage (B), an 
inverted microscope (C), a cell superfusion system (D) with a temperature control 
system (E), a video edge motion detector (F), a microfluorescence photometry 
system (G) and an electrical stimulator (H). 
 
49 
 
 
 
2.6 Whole-Cell Recordings 
   Whole-cell recordings were performed in isolated ventricular myocytes. The 
myocytes were placed in the recording chamber (0.4 mL) mounted on the stage of an 
inverted microscope (CK2, Olympus, Tokyo, Japan) (Figure 12). After settling to the 
bottom of the chamber, cells were superfused with an external solution for 10 min at a 
rate of 2–3 mL.min
-1
 at room temperature. The external solution contained (in mM) 120 
NaCl, 1 EGTA, 10 MgCl2, 10 Glucose, 10 HEPES, 1 NaH2PO4 and 5 KCl. 
Transmembrane currents were recorded with an axopatch amplifier 200 B (Axon 
Instruments, Inc., Foster City, CA, USA). The whole-cell bath solution contained (in 
mM): 95 NaCl, 50 TEACl, 2 MgCl2, 2 CaCl2, 10 HEPES and 10 Glucose (adjusted to 
pH 7.35 with NaOH). Glass microelectrodes were made using a microelectrode puller 
(Model P-97, Sutter Instrument Co.,Novato, CA, USA) (Figure 13) by two-stage pulling, 
and had a resistance of 2.0–4.0 MΩ when filled with electrode internal solution 
containing (in mM) 140 CsCl, 10 TEACl, 2 MgCl2, 2 HEPES 1 MgATP and 10 EGTA 
(adjusted to pH 7.25 with CsOH). Only rod shaped cells with clear cross-striations were 
used for the experiments. Figure 14 shows typical ventricular myocytes with patch 
pipette in solution. After gigaseal formation (1-10 GΩ) by suction through a pipette, the 
membrane was ruptured with a gentle suction to obtain the whole-cell voltage clamp 
configuration. Membrane capacitance and series resistance were compensated after 
membrane rupture to minimize the duration of capacitive current. The experiment was 
conducted under room Temperature (22-24 ºC). To record L-type Ca
2+
 currents, the 
external solution was changed to the Na
+
-free solution in which Na
+ 
was replaced by 
equimolar TEA (TEA–Cl). The Na
+ 
current was also inactivated at the holding potential -
50 mV. K
+
currents were suppressed by substituting K
+
 by Cs
+
. Computer-generated 
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voltage pulses were programmed using the pCLAMP 10.0 software (Axon Instruments). 
Cells with stable calcium currents were then tested using different drugs  
 
Figure 12. Patch clamp Setup 
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Figure 13. Microelectrode puller (model P-97, Sutter Instrument) 
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Figure 14. Glass electrode forming giga seal with ventricular 
myocyte 
 Figure 15. Ventricular myocyte 
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Chapter 3: Results 
3.1 Effects of Cannabidiol on Ventricular Myocyte Shortening 
In Normal Tyrode (NT) solution, amplitudes of myocyte shortening in response to 
electrical stimulation (1 Hz) gradually decreased to 85-80 % of controls during 
experiments lasting up to 20 minutes. No further running down of the shortening 
amplitude was observed in the NT solution containing 0.02 % DMSO. And, unless it 
stated otherwise, DMSO (in the concentration used in CBD containing solution) was also 
included routinely in the control NT solutions during the shortening and Ca
2+
 transient 
experiments. 
In initial control experiments and in line with earlier studies conducted under 
similar conditions it has been shown that 0.01 % DMSO did not significantly affect 
contractile parameters and Ca
2+
 current in rat ventricular myocytes(Sun et al., 2010). The 
application of control solution (NT) containing dimethyl sulfoxide at the highest 
concentration used in contractility studies (0.02 % v/v; used as vehicle for 1 μM CBD) 
caused 11-13 % inhibition of the shortening (n=7-10; P<0.05 compared to a 0 time 
point). 
In the first set of experiments, we tested the effect of CBD on the contractility of 
acutely isolated rat ventricular myocytes. Figure16A shows typical records of shortening 
in myocytes superfused with either NT (in the absence of CBD, NT contained 0.02 % 
DMSO in all experiments) or NT + 1 µM CBD and during washout with NT. The time 
frame of the effect of CBD on amplitude of shortening is shown in Figure 16B. The 
effect of CBD reached a steady level within 5 minutes of CBD application. Increasing the 
incubation time to 10 minutes did not cause any further change in the amplitude of 
shortening. Recovery from CBD inhibition was incomplete during the 5-10 minutes 
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washout time. In summary, the amplitude of shortening measured after 5 minutes bath 
application of CBD was significantly reduced (paired t-test; n=17; P<0.05) by up to 46.4 
± 3.1 % in the controls (Figure 16C). The effect of CBD increased in a concentration-
dependent manner. The concentration-response relationship normalized to maximal CBD 
inhibition indicated that CBD suppresses shortening of amplitudes with an IC50 of 0.6 
µM (Figure17). Among other contraction parameters measured, resting cell length 
(RCL), time to peak and time to half relaxation were not significantly altered 
(n=17; P>0.05) by 10 minutes superfusion with CBD. 
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Figure 16. Effects of cannabidiol on ventricular myocyte shortening. (A) Typical records of 
shortening in an electrically stimulated (1 Hz) ventricular myocytes superfused with either NT 
(containing the vehicle, 0.02% DMSO) or NT + 1 µM CBD and during washout with NT. (B) 
Time course of the mean amplitudes (AMP) of shortening expressed as a percentage of control 
values in vehicle (NT + 0.02% DMSO), and in presence of CBD (1 µM). Myocytes were 
maintained at 35-36 °C and superfused with CBD for 10 minutes. (C) Data shown as means ± 
S.E.M., n = 6-8 cells. * indicates statistically significant difference at the level of P< 0.05. 
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Figure 17. Concentration-inhibition relationship of cannabidiol effect on the shortening of 
myocytes. Concentration-response curve for the inhibitory effect of CBD on myocyte shortening. 
The data was normalized to maximal inhibitory effect of CBD and plotted as a function of CBD 
concentrations. Data are mean ± S.E.M. from n = 6-8 cells for each concentration. 
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3.2 Effects of Cannabidiol on Intracellular Ca2+ 
In the second set of experiments we investigated the effects of 5 minutes bath 
application of 1 µM CBD on the resting intracellular Ca
2+
 levels, and on the amplitudes 
and kinetics of Ca
2+
 transients elicited by electrical-field stimulation. Typical records of 
Ca
2+
 transients in a myocytes superfused with NT (containing 0.02 % DMSO), NT + 1 
µM CBD and during washout with NT are shown in Figure18A. The effects of 1 µM 
CBD on resting fura-2 ratio, TPK Ca
2+
 transient, THALF decay of the Ca
2+
 transient and 
AMP of Ca
2+
 transients are shown in Figure 18B-E, respectively. Although, CBD has 
been shown to alter intracellular Ca
2+
 levels in various types of cells (see Pertwee, 
2008;Pertwee, et al., 2010), application of 1 µM CBD for 5 to 10 minutes did not cause a 
significant alteration in resting fura-2 ratio, TPK Ca
2+
 transients, or THALF decay of the 
Ca
2+ 
transient (paired t-test; n=11-14 cells, P>0.05). However, the AMP of the Ca
2+
 
transient was significantly reduced by 1 µM CBD (0.337 ± 0.043 fura-2 ratio units) 
compared to 0.488 ± 0.056 fura-2 ratio units (paired t-test, n =11 cells) in the control 
experiments. 
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Figure18. Effects of cannabidiol on amplitude and time-course of intracellular Ca
2+
 in rat 
ventricular myocytes.(A) Typical records of Ca
2+
 transients in an electrically stimulated (1 Hz) 
ventricular myocytes superfused with either NT or NT + 1 µM CBD and during washout with 
NT; scale bar indicates 0.1 fura-2 ratio unit (RU). Also shown resting fura-2 ratio (340/380 nm) 
(B), time to peak (TPK) Ca
2+
 transient (C), time to half (THALF) decay of the Ca
2+
 transient (D) 
and amplitude of the Ca
2+
 transient (E). Myocytes were maintained at 35-36 °C and superfused 
with CBD for 10 minutes. Data are shown as means ± SEM, n=11-14 cell. * indicates statistically 
significant difference at the level of P< 0.05. 
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3.3 Effect of Cannabidiol on Sarcoplasmic Reticulum Ca2+ Transport 
The effect of CBD on sarcoplasmic reticulum Ca
2+
 transport was tested. 
Figure19A shows a typical record illustrating the protocol used in these experiments. 
Initially, the myocyte was electrically stimulated at 1Hz. Electrical stimulation was then 
turned off for 5 seconds. Caffeine was then applied for 10 seconds using a rapid solution-
exchanger device. Electrical stimulation was then restarted, and the recovery of 
intracellular Ca
2+
 was recorded during a 60 seconds period. The SR Ca
2+
 content was 
assessed by measuring caffeine-evoked Ca
2+
 release (under the caffeine-evoked Ca
2+
 
transient) and fractional release of Ca
2+
 by comparing the amplitude of the electrically 
evoked steady-state Ca
2+
 transients with that of the caffeine-evoked Ca
2+
 transient in the 
presence of either NT alone or NT with 1 µM CBD. Maximal amplitudes and the rates of 
Ca
2+
 release by 20 mM caffeine remained unaltered after a 10 minute bath application of 
1 µM CBD (Figure 19B) and (Figure 19C; paired t-test; n = 7 cells, P>0.05). Fractional 
release of SR Ca
2+ 
was not significantly altered in 1 µM CBD compared to NT (0.78 ± 
0.04 in CBD versus 0.81 ± 0.07 in controls; paired t-test; n =8 cells; Figure 19D). The 
recovery of the Ca
2+
 transients during electrical stimulation following application of 
caffeine (Figure19E) was also not significantly altered in myocytes exposed to 1 µM 
CBD myocytes compared to the control cells (paired t-test; n = 8 cells, P>0.05). 
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Figure19. Effect of cannabidol on sarcoplasmic reticulum Ca
2+ 
transport. (A) Typical records 
illustrating the experimental protocol. (B) Comparison of the effect of caffeine application on the 
area under caffeine-evoked Ca
2+
 transients in NT and CBD-treated ventricular myocytes. (C) 
Area under the curve. (D)Mean amplitude of SR fractional release of Ca
2+
. (E) Recovery of 
electrically evoked intracellular Ca
2+
 after application of caffeine. Data are mean ± S.E.M., n = 7-
8 cells. 
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3.4 Effect of Cannabidiol on Myofilament Sensitivity to Ca2+ 
 
The effects of CBD on myofilament sensitivity to Ca
2+
 were also investigated. 
These experiments tested whether CBD decreases the mechanical response by altering 
the affinity of the contractile machinery of the ventricular myocytes to intracellular Ca
2+
. 
Atypical record of myocyte shortening, fura-2 ratio and phase-plane diagrams of 
fura-2 ratio versus cell length in myocytes exposed to NT is shown in Figure 20A. The 
gradient of the trajectory reflects the relative myofilament response to Ca
2+
 and hence, 
has been used as a measure of myofilament sensitivity to Ca
2+
(Spurgeon, et al., 1992; 
Howarth, et al., 2002). The gradients of the fura-2-cell length trajectory during late 
relaxation of the twitch contraction measured during the periods 500-600 ms (Figure 
20B), 500-700 ms (Figure20C), and 500–800 ms (Figure20D) were not significantly 
altered in CBD compared to NT suggesting that myofilament sensitivity to Ca
2+
 is not 
reduced by CBD (CBD-treatment was compared to NT containing 0.02 % DMSO, paired 
t-test; n = 17 cells; P>0.05). 
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Figure 20. Effect of cannabidiol on myofilament sensitivity to Ca
2+
.(A) Typical record of 
myocyte shortening and fura-2 ratio and phase-plane diagrams of fura-2 ratio vs. cell length in a 
myocyte exposed to NT. The arrow indicates the region where the gradient was measured. B-D 
shows the effects of 1 µM CBD on the mean gradient of the fura-2 cell length trajectory of the 
twitch contraction during the periods 500-600 (B), 500-700 (C) and 500-800 ms (D) of late 
relaxation. Data are mean ± S.E.M., n = 17 cells. 
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3.5 Effects of Cannabidiol on the Action Potentials of Ventricular Myocytes 
In this set of experiments, patch-clamped ventricular myocyte were exposed to 
CBD while continuously monitoring their Vrest and APs in current clamp mode. The 
generation of APs was stimulated by 0.9-1 nA depolarizing current pulses of 4 ms 
durations. Since the intracellular pipette solution did not contain Ca
2+
-chelating agents, 
the generation of each AP was accompanied by a myocyte contraction. Therefore, current 
pulses were applied at a frequency of 0.2 Hz. During a typical experiment the following 
protocols were employed: first, whole-cell configuration was established and a 4 to 5 
minute dialysis of the myocytes with a pipette solution was allowed to ensure an 
equilibrium of conditions between the pipette solution and the intracellular milieu. After 
achieving stable recordings of baseline electrical activity (Vrest and AP parameters), 
myocytes were exposed to CBD for 5 to 10 minutes and was subsequently washed out.  
The resting membrane potentials (mean ± SEM) were -77.4 ± 1.9 and -79.2 ± 1.7 
mV in the control and after CBD treatment (n=9) myocytes, respectively (Figure 21A, 
inset and Figure 21B). Maximal amplitudes of AP and the rising rate of AP (maximal 
velocity; V/s, Figure 21C and Figure 21D) were not significantly altered in the presence 
of CBD. CBD (1 µM) consistently shortened the duration of AP (measured at 60 % of 
repolarization, APD60) (Figure 21A inset and Figure 21E). Changes in AP shortening in 
response to CBD (1 µM) applications were noticeable within 20 to 30 seconds 
(Figure21A). Recoveries were usually partial and required a longer time.  
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Figure 21. Effect of cannabidiol on the excitability of ventricular myocytes. (A) 
Representative recordings show the APs in controls (dark grey area), in the presence of 1 μM 
CBD (light grey area) and after washout (striped area) in a ventricular myocytes; the insets on 
panel A show the time course of action potential duration (APD60) and resting potential (Vrest) 
changes in response to CBD application (indicated by horizontal bars). (B-E) show summary of 
CBD effects on amplitude and shape of the AP in ventricular myocytes; quantification of the 
changes in Vrest(B), AP amplitude (C), AP maximal velocity(D) and AP duration (E), 
characterized by APD60 in controls (dark grey bars) and in response to 1 μM CBD (light grey 
bars). Data are mean ± S.E.M., n = 6 – 9 cells from 6 to 9 for each group. 
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3.6 Effect of Cannabidiol on L-type Ca2+ Currents 
We also investigated the effect of CBD (1 µM) on L-type Ca
2+
 currents. Figure 
22A shows a typical record of L-type Ca
2+
 currents elicited by applying a single 300 ms 
voltage pulse to +10 mV from a holding potential of -50 mV in rat ventricular myocyte 
before and after a 10 minute superfusion with 1µM CBD. The time frame of the effect of 
CBD on the density of L-type Ca
2+
 currents is shown in Figure 22B. The application of a 
vehicle (0.02% DMSO) for 10 minutes caused a 10-15% inhibition of the current density 
of L-type Ca
2+
 currents in experiments lasting up to 15 to 20 min. The effects of CBD 
were also investigated on the biophysical properties of L-type Ca
2+
 currents in rat 
ventricular myocytes. L-type Ca
2+
 currents were recorded in the presence of intracellular 
Cs
+
 and extracellular TEA
+
 to suppress K
+
 currents while retaining 95 mM Na
+
 in the 
extracellular solution. The elimination of contaminating Na
+
 current during the recording 
of L-type Ca
2+
 currents was achieved by applying voltage step-pulses from relatively 
depolarized Vh of -50 mV, which produced steady-state inactivation of sodium channels 
(Voitychuk, et al., 2012). As evident from the original recordings and I-V relationships 
(Figure23A), L-type Ca
2+
 currents started to appear at Vm = -30 mV, reached a 
maximum at around Vm = +10 mV, and decreased at higher voltages approaching to zero 
at about Vm = +60 mV (Figure23B). The maximal amplitudes of L-type Ca
2+
 currents 
were suppressed in the presence of CBD (1 µM).  
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Figure 22. Effect of cannabidiol on Ca
2+ 
currents mediated by L-type Ca
2+
 channels in rat 
ventricular myocytes.(A) CBD inhibits L-type Ca
2+
 currents recorded using whole-cell voltage-
clamp mode of patch clamp technique. Current traces are recorded before (control) and after 10 
min application of 1 μM CBD. L-type Ca
2+
currents were recorded during 300 ms voltage pulses 
to +10 mV from a holding potential of -50 mV. (B) Averages of the maximal currents of VGCCs 
presented as a function of time in the presence of vehicle (0.02% DMSO; filled circles) and 1 μM 
CBD (n=5 cells; open circles). Application time for the agents was presented in horizontal bars 
 
 
Figure 23. The effect of cannabidiol on voltage-current characteristics of L-type Ca
2+
 
channels in rat ventricular myocytes. (A) Representative recordings of L-type Ca
2+
currentsin 
response to the depicted pulse protocol under control conditions and after application of 1μM 
CBD. (B) Normalized and averaged I-V relationships of control L-type Ca2+ currents(filled 
circles) and L-type Ca2+ currents in the presence of 1 μM CBD (open circles) determined by 
applying a series of step depolarizing pulses from -70 mV to +70 mV in 10 mV increments for a 
duration of 300ms. Data points (mean ± S.E.M.) are from 5 to 7 cells. 
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CBD did not change the steady-state activation curve of the L-type Ca
2+
 current 
(V1/2 values in the control experiment and in the presence of CBD, they are -19.1 ± 0.4 
mV and -17.6 ± 0.3 mV, respectively; n=6, Paired t-test, P>0.05) (Figure 24A). However, 
there was a hyperpolarizing shift of L-type Ca
2+
 currents in steady-state inactivation by 
9.6 mV (i.e., from control value V1/2= -10.2 ± 0.9 mV to V1/2= -19.8 ± 1.1 mV in the 
presence of CBD) (Figure 24B). However, there was little effect on the slopes of the 
curves (k = 7.7 ± 0.5 mV and k = -4.5 ± 0.4 mV for the control activation and 
inactivation, respectively, versus k = 7.9 ± 0.3 mV and k = -4.2 ± 0.3 mV for the CBD-
modified activation and inactivation, correspondingly). 
In line with earlier reports (Soldatov, et al., 1998), kinetic analysis of L-type 
Ca
2+
currents were titled to a double-exponential function with fast (τf) and slow (τs) 
inactivation time constants. Comparison of L-type Ca
2+
 currents in the absence and 
presence of CBD revealed noticeable acceleration of the current's inactivation kinetics by 
CBD. Quantification of the time constants of L-type Ca
2+
 currents inactivation showed 
that CBD (1 μM) significantly reduced τi in the range of Vm -30 mV and +10 mV (Figure 
25). 
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Figure 24. Effect of cannabidiol on steady state activation and inactivation ofL-type Ca2+ 
currents in rat ventricular myocytes. Steady-state activation (A) steady-state inactivation (SSI) 
(B) curves of L-type Ca2+ currents in the absence (filled circles) and presence of 1 μM CBD 
(open circles). Data are mean ± S.E.M, n= 5 cells are from 5 cells. Fit of experimental data points 
with Boltzmann equation. 
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Figure25. Effect of cannabidiol on the kinetics ofL-type Ca2+currents in rat ventricular 
myocytes. Voltage-dependent fast (triangles) and slow (circles) inactivation time constants (τi) of 
L-type Ca2+ currents under control conditions (filled circles, and triangles) and in the presence of 
1 μM CBD (open circles and triangles). Data are mean ± S.E.M., n= 5-6 cells. 
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Chapter 4: Discussion 
Our results show that CBD has a negative inotropic effect on the contractility of rat 
ventricular myocytes. The negative inotropic effect of CBD appears to be mainly due to 
impaired Ca
2+
 signaling in cardiomyocytes. Furthermore, the results indicate that the 
impaired Ca
2+
 signaling emanates from the inhibitory effects of CBD on the function of L 
type Ca
2+
 channel.  
Actions of CBD on the cardiovascular system influences multiple organ systems 
and involves complex cellular and molecular mechanisms (see Baranowska-Kuczko, 
MacLean, Kozlowska and Malinowska, 2012; Stanley et al., 2013). CBD has been shown 
to have various effects on muscular structures, neuronal and endothelial cells and alter the 
activities of several receptors and ion channels directly (see Hejazi et al., 2006; Pertwee 
2008; 2010). Furthermore, other factors such as the activation of autonomic reflexes, the 
presence of endothelial cells and fatty-acid based metabolic products have been reported 
to contribute to the complexity of CBD actions on the heart (Pertwee 2008; Stanley et al., 
2013). On the other hand, acutely dissociated ventricular myocytes have several 
advantages over in-vivo and traditional in-vitro conditions, since it excludes some of the 
factors mentioned above and also the influences of reflex pathways, autonomic nerve 
endings, neurotransmitter uptake systems, gap-junction connections and coronary 
perfusion status.  
In our experiments, using video edge detection techniques in individual myocytes, 
it was found that CBD causes a significant reduction in the maximal amplitude of 
shortening (expressed as a percentage of resting cell length) without altering the time 
frame (such as TPK shortening and THALF relaxation) of myocytes shortening. Our 
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findings from myocyte shortening and intracellular Ca
2+
 measurement experiments are in 
agreement with earlier studies reporting that CBD exerts a negative-inotropic effect in 
isolated-cardiac muscle preparations (Smiley, Karler and Turkanis, 1976; Nahas and 
Trouve, 1985). Furthermore, results from our study suggest that a direct interaction of 
CBD with ventricular myocytes, rather than the actions of CBD on nerve endings and 
neurotransmitter uptake systems are mainly responsible for the negative inotropic effects 
of CBD in the heart.   
The negative-inotropic actions of CBD might be attributed to the impaired release 
of Ca
2+
 from the SR. In fact, CBD and other cannabinoids have been reported to 
modulate the ryanodine sensitive intracellular Ca
2+
 stores in neurons (Drsydale et al., 
2008) glia (Mato et al., 2010; Pertwee et al., 2010). However, the amplitude and kinetics 
of caffeine-induced Ca
2+
 release from intracellular Ca
2+
 stores were not changed by CBD 
suggesting that ryanodine-sensitive intracellular Ca
2+
 stores are not involved in the 
negative-inotropic effects of CBD observed in this study.  
Cannabidiol can alter the levels of second messengers such as cAMP, cGMP and 
protein kinase C which are known to be involved in tuning the Ca
2+
 sensitivity of the 
contractile proteins. In an earlier study of cardiac muscle membranes, cAMP levels have 
been shown to be unaltered in the presence of CBD (Hillard, Pounds, Boyer and Bloom, 
1990), Furthermore, the sensitivity of contractile proteins to intracellular Ca
2+
 remained 
unchanged in the presence of CBD suggesting that phosphorylation and de-
phosphorylation of the contractile proteins did not play a significant role in the negative-
inotropic action of CBD. Collectively, these results suggest that the effects of CBD on 
myocyte contractility are not related to changes in intracellular Ca
2+
 release machinery or 
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sensitivity of myofilaments to Ca
2+
. In addition, in the presence of CBD, resting levels of 
intracellular Ca
2+
, and cell length of ventricular myocytes, remained unaltered suggesting 
that CBD does not significantly affect Ca
2+
 homeostasis under resting conditions.  
During excitation-contraction coupling, alterations in the amplitudes and kinetics 
of the cardiac action potential (AP) are closely associated with corresponding changes in 
the contractility of myocytes. In our study, cardiac APs were recorded using the whole 
cell patch clamp technique. It was found that the amplitudes and dV/dtmax of APs were 
not altered in the presence of CBD suggesting that voltage-gated sodium channels are not 
affected by CBD. For this reason, the effect of CBD on the functional properties of 
voltage-gated sodium channels was not investigated any further. However, the decrease 
of AP duration, and suppression of the second phase of the AP was evident in whole cell 
recordings from cardiomyocytes. Since the plateau (phase 2) of AP is mainly due the 
influx of Ca
2+
 through L-type voltage-gated Ca
2+
channels, these results suggest that  
CBD can act on L-type Ca
2+
 channels. Indeed, whole cell recordings of Ca
2+
 currents in 
cardiomyocytes, in agreement with the recordings of APs, indicated that CBD inhibits 
potently the function of L-type voltage-gated Ca
2+
 channels with an IC50 value of 0.6 µM. 
An analysis of current kinetics indicated that the inactivation of Ca
2+
 currents can double 
the exponential decay and CBD can decrease the amplitudes of the Ca
2+
 currents by 
accelerating both fast and slow components of the inactivation process. The effects of 
CBD on the gating characteristics of Ca
2+
 channels were further investigated by studying 
the activation and inactivation curves in the absence and presence CBD. Although half 
activation voltage and the slope of the activation curve were not altered, there was a 
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hyperpolarizing-shift of the inactivation curve further suggesting that CBD changes the 
voltage-dependent inactivation process.    
Collectively, these results suggest that during excitation-contraction coupling, 
shortening of action potential due to the inhibition of L-type Ca
2+
 channels decreases 
Ca
2+
-induced Ca
2+
 release from SR and causes the negative-inotropic effect of CBD 
observed in our experiments and reported in earlier studies. In line with these findings, 
although caffeine induced contractures and myofilament sensitivity to Ca
2+
 remained 
unchanged, electrically-induced Ca
2+
 transients were significantly depressed by CBD; 
further suggesting that Ca
2+
-induced Ca
2+
 release was impaired in the presence of CBD. 
In earlier studies CBD has been reported to inhibit the uptake of dopamine and other 
neurotransmitters (Poddar and Dewey, 1980; Pandolfo, et al., 2011). However, an uptake 
mechanism is not likely to be involved in our studies on isolated ventricular myocytes. 
Furthermore, inhibition of uptake mechanisms for dopamine and/or catecholamines such 
as epinephrine and norepinephrine would lead to well-established positive inotropic 
actions, rather than a negative inotropic effect as observed in the present study.  
Although CBD does not activate known cannabinoid receptors, some of its 
pharmacological actions have been shown to be reversed by cannabinoid receptor 
antagonists (Pertwee, 2008). Recent studies have shown that the antagonist sensitivity of 
CBD effects is due to the inhibition of fatty acid amide hydrolase activity, an enzyme that 
inactivates endogenous cannabinoids and related to subsequent increases in tissue 
endocannabinoids levels (Pertwee, 2010). However, both amplitudes of myocyte 
shortening and the L-type Ca
2+
 currents were not altered by URB597, a potent inhibitor 
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of fatty acid amide hydrolase (Al Kury et al., 2014), suggesting that the activity of 
increased fatty acid amide hydrolase was not involved in the actions observed in CBD.  
The interaction between L-type Ca
2+
 channels and CBD has not been studied in 
detail. In an earlier study, 
45
Ca
2+
-uptake in brain synaptosomes had been shown to be 
inhibited by CBD (Harris and Stokes, 1982). Similarly, CBD induced increases in 
intracellular Ca
2+
 levels were found to be sensitive to blockers of L-type Ca
2+
 channels 
(Drysdale et al., 2006). In agreement with these results, contractions of smooth muscles 
elicited by high-K
+
-containing solutions were also significantly inhibited by CBD 
(Cluny, Naylor, Whittle and Javid, 2011). The interaction between T-type Ca
2+
 channels 
and CBD was investigated in a recent study, on human CaV3 channels stably expressed 
in human embryonic kidney 293 cells and T-type channels in mouse sensory neurons 
(Ross et al., 2008). At moderately hyperpolarized potentials, CBD inhibited peak CaV3.1 
and CaV3.2 currents with IC50 values of 1 µM but was less potent on CaV3.3 channels. 
CBD inhibited sensory neuron T-type channels by about 45% at 1 µM. However, in 
recordings made from a holding potential of -70 mV, 100 nM CBD inhibited more than 
50% of the peak CaV3.1 current. CBD produced a significant hyperpolarizing shift in the 
steady state inactivation potentials for each of the CaV3 channels (Ross et al., 2008). In 
this respect our results indicate for the first time that CBD inhibits the function of L-type 
Ca
2+
 channels in ventricular myocytes.    
In clinical studies, it has been shown that acute CBD intake does not cause a 
significant change in blood pressure and heart rate (Stanley, 2013a). However, several 
earlier studies indicate that increases in blood pressure and heart rate during stressful 
conditions are markedly attenuated by CBD (Gomes, et al., 2013; Granjeiro, Gomes, 
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Guimaraes, Correa and Resstel, 2011; Resstel, Joca, Moreira, Correa and Guimaraes, 
2006; Resstel, et al., 2009). In fact, in in vivo studies, it has been demonstrated that 
increased heart rate and blood pressure, one of the most consistent effects of cannabis 
intoxication, are significantly decreased by CBD (Nahas and Trouve, 1985). These 
studies suggest that CBD can exert negative inotropic and chronotropic actions under 
certain clinical conditions such as stress and cannabis intoxication.   
CBD, in the concentration range used in this study (0.1-10 µM), has been shown 
to modulate functions of various receptors and ion channels such as Ca
2+
 channels (Ross 
et al., 2008), 5-HT3 (Yang et al., 2010), and nicotinic receptors (Mahgoub et al., 2013). 
The peak plasma concentrations of CBD in healthy volunteers following administration 
of Sativex
TM
 (1:1 ratio of ∆9-THC and CBD) was reported to be between 0.01µM to 
0.05µM (Massi, et al., 2013). In earlier clinical studies, mean CBD levels of 0.036 μM 
were determined in blood analysis following a 6-week oral treatment with CBD at doses 
of 10 mg/kg/day (Consroe et al., 1991). However, CBD is a highly lipophilic compound 
and easily passes biological membranes and accumulates in tissues and it can reach to 
several fold higher tissue concentrations than in blood. Collectively, these findings 
suggest that CBD, at relatively high concentrations, can suppress the function of the 
cardiovascular system. In fact, cardiac failure due to depressed heart contractility has 
been suggested to be the main cause of mortality through cannabis intoxication 
(Bergamaschi et al., 2011). Thus it is likely that some of the effects of the cannabis plant 
are mediated by CBD during cannabis intoxication. 
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In addition to cardiac contractility, the electrical activity of heart has also been 
suggested to be affected by CBD. In an earlier study, CBD has been shown to have 
beneficial actions in ischemia-induced cardiac arrhythmias (Walsh et al., 2010). The 
shortening of the AP duration by CBD observed in our study can be beneficial or 
harmful, depending on the underlying pathology. Thus, during acute ischemia, in which 
the duration of the cardiac APD is already shortened, a further decrease should be 
proarrhythmic (Den Ruijter et al., 2007). However, shortening of AP duration should be 
beneficial in preventing those arrhythmias caused by triggered activities observed in 
conditions such as heart failure (Den Ruijter et al., 2007). In conclusion, the results 
indicate for the first time, that CBD inhibits myocyte contractility by acting on L-type 
Ca
2+
 channels. 
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Chapter 5: Limitation and Future Directions 
The scope of this research is mainly concerned with the effects of CBD on healthy 
ventricular cells, although endocannabinoids are stress induced neurotransmitters. In 
addition to the effects of CBD on L- type calcium channels its effect on NCX should also 
be established due to their influence on cytosolic calcium levels and the viability of 
ventricular cells in the presence of CBD. 
Future research may also include expressing calcium channels onto HEK-293 cells, 
this allows us to exclude or include the indirect effects of CBD on intracellular signaling 
that can affect calcium channels. Another method is to express the calcium channel each 
subunit at a time and find where CBD exerts it effects most effectively and thereby 
establish the mechanism by which CBD exerts there effects. 
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